Article
Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation - 1 Dec 2011
Gijsen Violette, Mital Seema, van Schaik Ron H, Soldin Offie P, Soldin Steven J, van der Heiden Ilse P, Nulman Irena, Koren Gideon, de Wildt Saskia N
Abstract excerpt
BACKGROUND: Tacrolimus is one of the commonly used immunosuppressive drugs for pediatric heart transplants. Large variation exists in pharmacokinetics during the direct post-transplant period, resulting in an increased risk of adverse events. Limited data are available on the interaction of age, CYP3A5 and ABCB1 genotype, and disease severity on the variation in disposition and outcome in pediatric heart...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.